KAITLYN CHITTICK-MYERS: Open Payments
NPI 1790301257 · WABASH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,368 in 89 payments from 13 companies in 2025. Trend: 2023 $1,061 · 2024 $1,621 · 2025 $1,368
Food & beverage: $1,319Education: $49
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $279 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $229 |
| Otsuka America Pharmaceutical, Inc. | 11 | $190 |
| Alkermes, Inc. | 13 | $171 |
| Lundbeck LLC | 15 | $142 |
| Axsome Therapeutics, Inc. | 9 | $137 |
| Vanda Pharmaceuticals Inc. | 3 | $47 |
| Corium, LLC | 3 | $42 |
| ABBVIE INC. | 2 | $39 |
| Orexo US, Inc. | 2 | $35 |
Products named: REXULTI, CAPLYTA, TRINTELLIX, ARISTADA, Auvelity, Azstarys, ABILIFY ASIMTUFII, VRAYLAR.
Industry payments across IN — which companies pay providers there.
